First Patient Treated in RP-1664 Phase 1 Trial by Repare Therapeutics

Repare Therapeutics Inc., a precision oncology company in the clinical-stage, has started dosing patients in its Phase 1 study named LIONS. This study explores the effectiveness of RP-1664, a selective oral inhibitor of polo-like kinase 4 (PLK4), targeting adult and adolescent patients with TRIM37-high solid tumors.

"RP-1664 has shown significant tumor reduction and regressions in preclinical models of TRIM37-high solid tumors and neuroblastoma, as demonstrated in collaboration with Children’s Hospital of Philadelphia," stated Maria Koehler, MD, PhD, Executive Vice President and Chief Medical Officer of Repare. She noted the swift progression to a Phase 1/2 trial, especially focusing on high-risk, recurrent pediatric neuroblastoma patients who have TRIM37 alterations and limited treatment choices.

The LIONS clinical trial (NCT06232408) is an open-label, multicenter Phase 1 study aimed at investigating the safety, pharmacokinetics, pharmacodynamics, and initial effectiveness of RP-1664. Around 80 patients with advanced solid tumors containing TRIM37 genetic alterations will be enrolled. The main objectives include determining the safety, tolerability, dosage, and schedule of RP-1664, alongside early signs of antitumor activity.

About RP-1664

RP-1664 is an innovative, highly selective oral PLK4 inhibitor focused on exploiting the synthetic lethal relationship with TRIM37 amplification or overexpression found in solid tumors. During preclinical trials, RP-1664 proved to inhibit PLK4 effectively and caused strong synthetic lethality in TRIM37-high tumor models.

About Repare Therapeutics’ SNIPRx® Platform

Repare’s SNIPRx® platform is a CRISPR-enabled screening tool that identifies novel and known synthetic lethal gene pairs, and helps determine patients most likely to benefit based on their tumor’s genetic make-up. This platform facilitates the development of targeted therapies that address specific genomic alterations, thereby increasing the potential clinical benefits for patients.

About Repare Therapeutics, Inc.

Repare Therapeutics is a pioneer in precision oncology, leveraging synthetic lethality to discover and develop new cancer treatments. Utilizing its CRISPR-enabled SNIPRx® platform, Repare Therapeutics focuses on genomic instability and DNA damage repair pathways. The company's product pipeline includes lunresertib (RP-6306), camonsertib (RP-3500), RP-1664, and RP-3467, as well as other undisclosed preclinical programs.

This company aims to provide new treatment options through their innovative precision therapeutic solutions, with multiple candidates in various stages of clinical development.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!